Because innovation fuels our pipeline
As we think about the future of medicine, we’re exploring new frontiers across a diverse and robust range of product candidates and disease states. All with the vision of developing game-changing solutions for patients.
| Candidate | Target | Isotope | Indication/Disease Area | Pre-clinical | Phase I | Phase II | Phase III | Reg. Filing | |
|---|---|---|---|---|---|---|---|---|---|
| Prostate Cancer |
|
GRPR | 68Ga | Metastatic Prostate Cancer | |||||
|
LNTH-2401 is a novel radiodiagnostic targeting the gastrin-releasing peptide receptor. |
|||||||||
|
GRPR | 177Lu | Metastatic Prostate Cancer | ||||||
|
LNTH-2402 is a novel gastrin-releasing peptide receptor targeted radiotherapeutic for solid tumors including prostate, breast, lung and other cancers. |
|||||||||
| Neuroendocrine Tumors |
|
SSTR2 | 177Lu | GEP-NETs | |||||
|
PNT2003 is a somatostatin receptor targeted radiotherapeutic, in development for gastroenteropancreatic neuroendocrine tumors. |
|||||||||
|
SSTR2 | 68Ga | NETs | ||||||
|
LNTH-2501/EVG-001 is an investigational kit for the preparation of Gallium-68 DOTATOC which may be used in conjunction with a PET scan to stage and localize SSTR+ neuroendocrine tumors in adults and children. |
|||||||||
| Other Solid Tumors |
|
FAP | 64Cu | Tumor / Fibrosis assessment | |||||
|
LNTH-1363S is a fibroblast activation protein, copper-64 labeled radiodiagnostic with broad potential imaging applicability and use in oncology. |
|||||||||
|
LRRC15 | Undisc. | Solid Tumors | ||||||
|
LNTH-2403 is a Leucine-Rich Repeat-Containing Protein 15 targeted radiotherapeutic. It received Orphan Drug and Rare Pediatric Disease designations from the U.S. FDA for the treatment of osteosarcoma. |
|||||||||
|
TROP2 | Undisc. | Solid Tumors | ||||||
|
LNTH-2404 is a Trophoblast cell surface antigen-2 targeted radiotherapeutic. |
|||||||||
|
CCK2R | 177Lu/68Ga | Small Cell Lung Cancer | ||||||
|
LNTH-2503/EVG-321 is a highly specific peptide vector, which binds to the cholecystokinin-2 receptor (CCK2), a highly expressed tumor marker in cancers like small cell lung cancer (SCLC). |
|||||||||
|
Undisc. | 177Lu/68Ga | Glioblastoma | ||||||
|
LNTH-2505/EVG-311 is a molecularly targeted tracer that binds to a glial cell surface molecule which may be used for the diagnosis and treatment of glioblastoma (GBM) and potentially other glial tumors. |
|||||||||
|
Undisc. | 177Lu/68Ga | Pancreatic Ductal Adenocarcinoma | ||||||
|
LNTH-2507/EVG-332 is a radiotracer targeting a cell surface molecule for the treatment of pancreatic ductal adenocarcinoma (PDAC). |
|||||||||
|
Undisc. | 177Lu/68Ga | Lobular Breast Cancer | ||||||
|
LNTH-2509/EVG-341 is a radiotracer targeting a cell surface molecule for the treatment of lobular breast cancer. |
|||||||||
| Neurology / Other |
|
Tau | 18F | Alzheimer’s Disease | |||||
|
Florquinitau is a next-generation tau-targeting radiodiagnostic for Alzheimer’s disease. |
|||||||||
|
ß amyloid | 18F | Alzheimer’s Disease | ||||||
Each of these product candidates is an investigational drug that has not yet been approved as safe and effective.
GRPR, Gastrin-releasing peptide receptor; SSTR2, Somatostatin receptor 2; GEP-NETs, Gastroenteropancreatic neuroendocrine tumors; FAP, Fibroblast activation protein; LRRC15, Leucine-rich repeat-containing protein 15; TROP2, Trophoblast cell surface antigen-2; CCK2R, cholecystokinin-2 receptor.
1. Also known as 68Ga-RM2 2. Also known as 177Lu-RM2 3. Collaboration with POINT Biopharma Global Inc.
*We are actively partnering with researchers on these assets to provide appropriate biomarkers in relevant studies. If interested, please contact biomarkers@lantheus.com for more information.